Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
| Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | |||
| Celsentri | Maraviroc | HIV | Withdrawn | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis | Withdrawn | |||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
| VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | |||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Withdrawn |
Last Updated : April 28, 2024